Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened

Shares of Travere Therapeutics took a hit Tuesday after fewer than expected patients started treatment with its kidney drug, Filspari. The post Travere Is On A Crash Course With Its 200-Day Line — Here's What Happened appeared first on Investor's Business Daily.